Gene therapy company Regenxbio Inc. of Rockville signed an agreement with AveXis Inc., a gene therapy company based in Chicago, for the development and sale of products to treat spinal muscular atrophy.
The agreement expands upon a 2014 deal between the firms.
In the new deal, Regenxbio gave AveXis rights to all vectors in its NAV technology platform for the treatment of that disease. Also, the rights can be assigned if AveXis has a change in control.
Regenxbio will get $80 million, plus annual payments of $30 million for two years. Additionally, Regenxbio may receive potential commercial milestone payments worth up to $120 million.
For products using the NAV AAV9 vector, Regenxbio will still get mid-single to low double-digit royalties. For any product developed for the treatment of the disease using a different NAV vector, Regenxbio will receive a low double-digit royalty.
AveXis is testing a gene therapy candidate that uses the NAV AAV9 vector.